Health Secretary Robert F. Kennedy Jr. publicly endorsed the Trump administration's deal to lower prices and expand access to GLP-1 weight loss drugs, marking a significant shift from his previous skepticism. The agreement aims to include Medicare and Medicaid coverage for medications produced by Eli Lilly and Novo Nordisk. Kennedy described the drugs as a 'tool' rather than a 'silver bullet,' surprising many supporters of his 'Make America Healthy Again' movement who expected him to oppose pharmaceutical interventions.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.